Sign In
21 Jun 2013 14:47
21 June 2013 |
ALLIANCE PHARMA PLC
("Alliance" or the "Company")
Director Shareholding
Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, was notified today that John Dawson, Chief Executive, has today sold 460,000 ordinary shares of 1p each in the Company ("Ordinary Shares") at a price of 35 pence.
Following this transaction, Mr Dawson has a beneficial interest in 39,576,402 Ordinary Shares representing 15.75% of the Company's issued share capital and a non-beneficial interest in 20,000,000 Ordinary Shares representing 7.96% of the Company's issued share capital.
For further information:
Alliance Pharma plc | + 44 (0) 1249 466966 | |
John Dawson, Chief Executive | ||
Richard Wright, Finance Director | ||
www.alliancepharma.co.uk | ||
Buchanan | + 44 (0) 20 7466 5000 | |
Mark Court / Fiona Henson / Sophie Cowles | ||
Numis Securities Limited | + 44 (0) 20 7260 1000 | |
Nominated Adviser: Michael Meade / Oliver Cardigan / Freddie Barnfield | ||
Corporate Broking: David Poutney | ||
Notes to editors:
About Alliance
Alliance, founded in 1998, is an AIM listed speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The Company has a strong track record of acquiring the rights to established niche products and owns or licenses the rights to more than 60 products and continues to explore opportunities to expand the range.
Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.
Follow the stocks
